Nav: Home

ICSI has no outcome benefits over conventional IVF in routine non-male infertility cases

June 26, 2019

Vienna, 26 June 2019: Intracytoplasmic sperm injection (ICSI), the world's favoured means of fertilisation in assisted reproduction, offers no benefit over conventional in vitro fertilisation in fertility treatments without a male factor indication, according to results of a large multicentre study.

ICSI was developed throughout the 1990s as a specific treatment for infertility of male cause.(1) Until then, men with poor quality or insufficient sperm cells in their ejaculate had little chance of fathering their own children. But now, in the hands of the ICSI embryologist and beneath powerful microscopes, just one sperm cell might be enough for conception.

Since its development, however, ICSI has been adopted as a fertilisation technique for all types of sub-fertility, and not just of male cause. Globally, ICSI cycles now outnumber conventional IVF cycles by around two to one, and in some countries - in the Middle East, for example - assisted reproduction cycles are entirely ICSI.(2)

Now, a large population-based study of almost 5000 patients in Belgium and Spain being treated with ICSI or standard IVF has found no benefit from ICSI in terms of fresh and cumulative live birth rate in non-male factor cases. The results of the study are presented today at the Annual Meeting of ESHRE by Dr Panagiotis Drakapoulos from UZ Brussels, the pioneering Belgian centre at which ICSI was developed more than 25 years ago. The study was a collaboration between the Brussels centre and 14 IVI clinics in Spain.

This important study did not just compare outcomes in ICSI and IVF in non-male factor cases but also in different kinds of patient response to ovarian stimulation. 'There has been a worldwide increase in the use of ICSI for all causes of infertility,' explained Dr Drakapoulos. 'The rationale for this seems to be that ICSI is associated with a higher likelihood of fertilisation and an increased number of embryos - but this is controversial. For example, ICSI is the first choice for fertilisation in many centres in patients who respond mildly to ovarian stimulation and have few eggs retrieved. But there is currently no evidence on the comparative effectiveness of ICSI and IVF according to the number of oocytes retrieved in patients with non-male factor infertility. This study for the first time aimed to provide that evidence using a large sample size.'

Results firstly showed no overall difference in outcome (fertilisation rate, live birth rate and cumulative live birth rate) in the ICSI or standard IVF cycles. Moreover, these comparable findings were also evident in four different patient response categories ranging from poor responders (1-3 eggs retrieved) to high responders (more than 15 eggs retrieved). 'It's clear from these results,' said Dr Drakapoulos, 'that the number of oocytes retrieved has no value in the selection of the insemination procedure in cases of non-male infertility', confirming that ICSI will not improve outcome in cycles in which only a few eggs are retrieved.

Both global and European registry figures show that around 70% of all reported cycles were ICSI in 2015, with a slightly higher pregnancy rate found in the IVF cycles (27.7% IVF and 25.5% ICSI). However, these usage rates varied from region to region, with high rates of ICSI evident in many countries of Eastern and Mediterranean Europe. More modest use, with a roughly 50-50 split between IVF and ICSI, was found in some Nordic countries, UK and France. In its latest review of treatment trends in the UK, the HFEA reported that ICSI use 'continued to increase until 2014, but it is now in decline, possibly due to clinical opinion that it's not needed in all contexts of IVF'.

This is indeed the clinical message from this study, which, according to Dr Drakapoulos, found 'no justification for the use of ICSI in non-male factor infertility'. He added that the number of eggs retrieved 'should not play any role in selecting the insemination method'.

'The rationale for the high use of ICSI in non-male factor cases,' he said, 'is based on a wrong assumption that ICSI may be associated with a higher likelihood of fertilisation and an increased number of available embryos. However, our results show that this assumption is misplaced.'

Dr Drakapoulos described these results as sufficiently robust 'to convince clinicians not to propose ICSI in all infertile patients', adding that the extra financial cost of ICSI over IVF should also be considered in the absence of male factor infertility.
Abstract O-228, Wednesday 26 June 2019

ICSI does not offer any benefit over conventional IVF across different ovarian response categories: a European multicenter analysis

Background notes

1. ICSI, a fertilisation technique in which a single sperm cell is injected into a mature egg with the guidance of powerful microscopes, was discovered serendipitously at the UZ-Brussel. It proved a revolution in ART because from then on male factor infertility (which accounts for as many as one-third of all cases) became amenable to treatment. The technique was developed in Brussels, with first live births described in The Lancet in 1992 (Palermo G, Joris H, Devroey P, Van Steirteghem AC. Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet 1992; 340: 17-18)

2. Data from ESHRE's own European assisted reproduction (ART) monitoring show that in 2015 around 70% of all cycles reported in Europe were ICSI (from a total of almost 500,000 cycles, 356,351 were ICSI, and 131,221 IVF). The ICSI cycles had a slightly lower pregnancy rate than the IVF (27.7% IVF and 25.5% ICSI). High rates of ICSI use were found in many countries of Eastern and Mediterranean Europe (eg, Czech Republic 100%, Malta 100%, Poland 90%, Italy 85%). More modest usage rates, with a roughly 50-50 split between IVF and ICSI, were found in most Nordic countries, UK and France.

* When obtaining outside comment, journalists are requested to ensure that their contacts are aware of the embargo on this release.

For further information on the details of this press release, contact:

Christine Bauquis at ESHRE
Mobile: +32 (0)499 25 80 46

European Society of Human Reproduction and Embryology

Related Infertility Articles:

Chlamydia in testicular tissue linked to male infertility
The potential impact of undiagnosed sexually transmitted chlamydia infection on men's fertility has been highlighted in a study led by scientists at Queensland University of Technology (QUT), which for the first time found chlamydia in the testicular tissue biopsies of infertile men whose infertility had no identified cause.
Infertility's roots in DNA packaging
Japanese researchers find one cause of infertility is the incomplete development of the proteins packaging DNA in sperm cells.
Infertility is linked to small increased risk of cancer
A study of over 64,000 women of childbearing age in the USA has found that infertility is associated with a higher risk of developing cancer compared to a group of over three million women without fertility problems, although the absolute risk is very low at just 2 percent.
Breakthrough in understanding male infertility
Newcastle University experts have identified the importance of gene, RBMXL2, which is similar to an infertility gene found on the Y chromosome, in regulating the production of fully-functioning sperm.
Duration of infertility in men may affect sperm count
A longer duration of infertility was associated with lower sperm count and other parameters of impaired sperm in a BJU International study of 1644 infertile men.
UCLA research may explain some causes of infertility and miscarriage
A new study in the journal Nature Cell Biology has uncovered information about a key stage that human embryonic cells must pass through just before an embryo implants.
Asthma medication linked to infertility in women
Women with asthma who only use short-acting asthma relievers take longer to become pregnant than other women, according to international research led by the University of Adelaide.
New Lancaster study 'reimagines infertility'
New research from Lancaster University has identified the 'invisible infertile', a group of marginalized people missing from survey data sources because they do not fit neatly into popular notions of who is at risk of infertility.
Infertility linked to higher risk of death among women
Women with a history of infertility have a 10 percent increased risk of death compared to those without reported infertility struggles, according to results of a new study from researchers at the Perelman School of Medicine at the University of Pennsylvania.
New technique overcomes genetic cause of infertility
Scientists have created healthy offspring from genetically infertile male mice, offering a potential new approach to tackling a common genetic cause of human infertility.
More Infertility News and Infertility Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.